VA
ARTV

VR Adviser’s Artiva Biotherapeutics ARTV Stock Holding History

VR Adviser’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.8M Buy
2,043,596
+434,027
+27% +$3.95M 0.6% 24
2026
Q1 		$10.4M Hold
1,609,569
– – 0.39% 32
2025
Q4 		$6.91M Hold
1,609,569
– – 0.34% 26
2025
Q3 		$4.62M Hold
1,609,569
– – 0.26% 31
2025
Q2 		$2.43M Hold
1,609,569
– – 0.18% 29
2025
Q1 		$4.83M Hold
1,609,569
– – 0.41% 27
2024
Q4 		$16.2M Hold
1,609,569
– – 1.11% 22
2024
Q3 		$24.9M Buy
+1,609,569
New +$18.7M 1.3% 22

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return

VR Adviser's ARTV Position: Q2 2026 in Review

VR Adviser increased its Artiva Biotherapeutics (ARTV) stake by 27% in Q2 2026, buying an estimated $3.95M and bringing the position to 2,043,596 shares worth $19.8M. The position accounts for 0.6% of the portfolio, ranked #24.

VR Adviser first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.9M in Q3 2024. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • VR Adviser held 2,043,596 shares of Artiva Biotherapeutics worth $19.8M as of Q2 2026.
  • VR Adviser bought 434,027 Artiva Biotherapeutics shares in Q2 2026, an estimated $3.95M.
  • Artiva Biotherapeutics made up 0.6% of VR Adviser's portfolio in Q2 2026, its #24 holding.
  • VR Adviser first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • VR Adviser's Artiva Biotherapeutics position peaked at $24.9M in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on VR Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.